Maccacaro, Torino, Italy, 5Janssen Cilag SpA, Cologno Monzese, Milan, Italy, 6PBE consulting, Verona, Italy, 7Erasmus University Medical Center, Soest, The Netherlands, 8Centre of Pharmacoeconomics, Milan, Italy pgA345 MH7 PATIENT REPORTED OBJECTIVES AND PRIORITIES FOR THE TREATMENT OF SCHIZOPHRENIA IN GERMANY A MIXED METHODS APPROACH TO CAPTURING THE PATIENT S PERSPECTIVE Kinter ET1, Rudolph I2, Schmeding A2, Bridges JF1, 1Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA, 2Janssen Cilag GmbH, Neuss, Germany pgA345 MH8 DIRECT COST OF TREATING PATIENTS WITH SCHIZOPHRENIA IN GREECE REAL WORLD DATA FROM THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY E STAR Geitona M1, Kousoulakou C2, Ollandezos M3, Papanicolaou S4, Athanasakis K3, Tsiantou V3, Kyriopoulos J3, 1University of Thessaly, Volos, Greece, 2Foundation for Economic and Industrial Research, Athens, Greece, 3National School of Public Health, Athens, Greece, 4Janssen Cilag Pharmaceutical SACI, Athens, Attika, Greece Modelling in Economic Evaluation Terpsichore ABC Moderator Magdalini Hatzikou, BA, MBA, Pricing, Reimbursement and Health Outcome Manager, Novartis Hellas and Research Associate, Economics Department, University of Thessaly and Treasurer of the Hellenic Society for Pharmacoeconomics ISPOR Greece Chapter, Athens, Greece pgA346 MO1 ADVANTAGES AND DISADVANTAGES OF MARKOV MODELS VERSUS DISCRETE EVENT MODELS FOR SIMULATING PATIENT FLOWS Al MJ1, Welte R2, 1Erasmus MC, Rotterdam, The Netherlands, 2GlaxoSmithKline, Munich, Germany pgA346 MO2 INCORPORATING CALIBRATED MODEL PARAMETERS INTO SENSITIVITY ANALYSES DETERMINISTIC AND PROBABILISTIC APPROACHES Taylor DC1, Kruzikas D2, Pawar V3, Gilmore K1, Naik S1, Weinstein MC4, 1i3 Innovus, Medford, MA, USA, 2GlaxoSmithKline, Philadelphia, PA, USA, 3Innovus Research, Inc, Medford, MA, USA, 4i3 Innovus Research Inc <a href=
https://enhanceyourlife.mom/>priligy 30mg tablets</a>